| Literature DB >> 32291133 |
Matthew B Calvert1, Daniel P Furkert2, Christopher B Cooper3, Margaret A Brimble4.
Abstract
Bedaquiline is a diarylquinoline drug that demonstrates potent and selective inhibition of mycobacterial ATP synthase, and is clinically administered for the treatment of multi-drug resistant tuberculosis. Due to its excellent activity and novel mechanism of action, bedaquiline has been the focus of a number of synthetic studies. This review will discuss these synthetic approaches, as well as the synthesis and bioactivity of the numerous derivatives and molecular probes inspired by bedaquiline.Entities:
Keywords: Bedaquiline; Diarylquinolines; SAR; Stereoselective synthesis; Tuberculosis
Year: 2020 PMID: 32291133 DOI: 10.1016/j.bmcl.2020.127172
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823